A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Exclusion Criteria

• •1. Women who are pregnant or breastfeeding
• •2. Current isolated central nervous system (CNS) involvement
• •3. Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except CAR T-cell therapy in CAR T-exposed subjects)
• •4. History of or active human immunodeficiency virus (HIV)
• •5. Active hepatitis B or C
• •6. Systemic autoimmune or immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease
• •7. Ongoing CNS disease that would preclude neurologic assessment
• •8. Uncontrolled angina or other acute heart disease
• •9. Currently receiving treatment in another interventional clinical trial.